Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 8,664,231

« Back to Dashboard

Which drugs does patent 8,664,231 protect, and when does it expire?

Patent 8,664,231 protects RASUVO and is included in one NDA.

This patent has twenty-four patent family members in nineteen countries.

Summary for Patent: 8,664,231

Title:Concentrated methotrexate solutions
Abstract: Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 30 mg/ml. The invention also relates to a ready-made syringe and a carpule containing such a pharmaceutical solution formulation, as well as a pen injector comprising such a carpule and/or a ready-made syringe.
Inventor(s): Will; Heiner (Hamburg, DE)
Assignee: Medac Gesellschaft fuer Klinische Spezialpraepararate mbH (Wedel, DE)
Application Number:12/374,528
Patent Claim Types:
see list of patent claims
Use; Formulation; Device; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Medac Pharma Inc
RASUVO
methotrexate
SOLUTION;SUBCUTANEOUS205776-001Jul 10, 2014RXNoNo8,664,231► Subscribe SUBCUTANEOUS INJECTION OF METHOTREXATE
Medac Pharma Inc
RASUVO
methotrexate
SOLUTION;SUBCUTANEOUS205776-002Jul 10, 2014RXNoNo8,664,231► Subscribe SUBCUTANEOUS INJECTION OF METHOTREXATE
Medac Pharma Inc
RASUVO
methotrexate
SOLUTION;SUBCUTANEOUS205776-003Jul 10, 2014RXNoNo8,664,231► Subscribe SUBCUTANEOUS INJECTION OF METHOTREXATE
Medac Pharma Inc
RASUVO
methotrexate
SOLUTION;SUBCUTANEOUS205776-004Jul 10, 2014RXNoNo8,664,231► Subscribe SUBCUTANEOUS INJECTION OF METHOTREXATE
Medac Pharma Inc
RASUVO
methotrexate
SOLUTION;SUBCUTANEOUS205776-005Jul 10, 2014RXNoNo8,664,231► Subscribe SUBCUTANEOUS INJECTION OF METHOTREXATE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,664,231

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2006 033 837Jul 21, 2006
PCT Information
PCT FiledJuly 20, 2007PCT Application Number:PCT/EP2007/006491
PCT Publication Date:January 24, 2008PCT Publication Number: WO2008/009476

International Patent Family for Patent: 8,664,231

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria14872► Subscribe
Austria491455► Subscribe
Australia2007276387► Subscribe
BrazilPI0715433► Subscribe
Canada2659662► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc